Publication number: 20230257383
Abstract: A compound serving as a BTK inhibitor, a preparation method therefor, and a use thereof. The compound has a structure represented by formula I, or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture thereof, or a pharmaceutically acceptable hydrate, solvent, or salt thereof, wherein A1, A2, A3, A4, A5 and A6 are each independently selected from C—R5 and N, and at least one of those is N; and M is selected from substituted or unsubstituted saturated or heterosaturated hydrocarbyl, substituted or unsubstituted unsaturated cyclic group or heterocyclyl, and substituted or unsubstituted monocyclic, bicyclic, or tricyclic aryl or heteroaryl. The provided BTK protein kinase inhibitor has strong inhibition for wild BTK and mutated BTK (C481S), has good pharmacokinetic properties, and has good application prospects.
Type:
Application
Filed:
July 13, 2021
Publication date:
August 17, 2023
Applicants:
CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD., SHENZHEN HYPERWAY PHARMACEUTICALS CO., LTD.
Inventors:
Chunchao YUE, Guanfeng LIU, Shai LI, Jing LI, Gang CHEN, Yangtong HE, Rui ZHANG, Chenguang YUAN, Yingfu LI